Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall by more than 40% on July 18, 2025 [5].

Sarepta restructures $700 million debt, easing financial strain after controversy over gene therapy Elevidys https://t.co/0B6cqhiO3n ...

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, resulting in a stock price drop of over 40% on July 18, 2025 [5].

The right to try movement had powerful allies in the Trump administration as they fought to regain access to Sarepta's Elevidys https://t.co/wDUwyTfmWp ...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its primary product for Duchenne muscular dystrophy [3]. - Allegations state that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while in reality, it has caused fatal acute liver failure in some patients [3]. Group 3: Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock fell by $27.81, or over 27%, from $101.35 to $73.54 [4]. - After a second patient death was reported on June 15, 2025, the stock dropped by $15.24, or more than 42%, from $36.18 to $20.94 [4]. - A third patient death related to Elevidys was disclosed on July 17, 2025, leading to a further decline of over 40% in stock price on July 18, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to lead the case [2]. Group 2: Product and Safety Claims - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its primary product for Duchenne muscular dystrophy [3]. - The company allegedly misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it has been linked to fatal acute liver failure in some patients [3]. Group 3: Stock Price Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock fell by $27.81, or over 27%, from $101.35 to $73.54 [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to drop by more than 40% on July 18, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall by more than 40% on July 18, 2025 [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - The complaint alleges that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while in reality, it has caused fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to Elevidys on March 18, 2025, Sarepta's stock plummeted by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, resulting in a stock drop of over 40% on July 18, 2025 [5].